Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30715911 | 0.92 | MMP13 (0.48) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL30797482 | 0.87 | MMP13 (0.45) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL30744722 | 0.86 | MMP13 (0.48) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL31195332 | 0.83 | MMP13 (0.46) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL30816123 | 0.79 | MMP13 (0.46) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL27087358 | 0.78 | GCGR (0.42) | MMP13ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL4070785 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2LMNAGALR2 | |
| SCHEMBL30751749 | 0.77 | MMP13 (0.48) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL30761773 | 0.77 | MMP13 (0.48) | MMP13ALDH1A1HPGDMMP2MMP14 | |
| SCHEMBL30910161 | 0.76 | KDM4E (0.42) | ALDH1A1HPGDSMN1; SMN2POLBGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180209-B1 | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2024-12-31 | — | — | US | disclosed |
| US-12173003-B1 | Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2024-12-24 | — | — | US | disclosed |
| US-11945820-B1 | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173003-B1 | Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CKS2 | MMP13 3728/4885ALDH1A1 4307/4885HPGD 3339/4885 |
| US-11945820-B1 | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CKS2 | MMP13 3728/4885ALDH1A1 4307/4885HPGD 3339/4885 |
| US-12180209-B1 | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CKS2 | MMP13 3728/4885ALDH1A1 4307/4885HPGD 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.